Welcome to the 2nd Interstitial Lung Disease Drug Development Summit

Thank you to our speakers, sponsors, and delegates who joined us for the summit! If you are interested in the 2023 event, please get in touch at info@hansonwade.com

With SSc-ILD on the cusp of regulatory approval following closely behind Pirfenidone’s breakthrough therapy designation to treat uILD last year, and investment pouring across multiple ILD phenotypes, the time is now to ramp up your therapeutic development against sarcoidosis, hypersensitivity pneumonitis, SSc-ILD and other interstitial lung diseases.

With 3 unique days of dedicated scientific content - from discovering how to strategically optimize your approach to treating inflammatory vs fibrotic ILDs to learning how to leverage clinical trials to identify novel outcomes and investigating the transformative power of machine learning for ILD imaging – this is the only meeting dedicated to helping you drive forward the development of effective therapies for inflammatory/chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF.

Agenda Highlights Included

  • Analyzing biologics, small molecules & antibodies for the treatment of ILD with Pieris Pharmaceuticals & Trinity College Dublin to determine which one is most easily inhaled, nebulized & absorbed by the alveoli
  • Learning how to use biomarkers to distinguish patients with fibrotic vs inflammatory ILD with Genentech to strategically stratify trial populations & maximize trial efficiency
  • Investigating how to effectively leverage ILD clinical trials to further our understanding of the progressive pulmonary fibrosis phenotype and discovering key considerations for trial design in sarcoid with Novartis & Boehringer Ingelheim to streamline your clinical research
  • Uncovering emerging ILD therapeutic approaches including anticalins, VP01 (C21) and GSNOR inhibition with Vicore Pharma, SAJE Pharma & Pieris Pharmaceuticals to understand how you can utilize the latest research to innovate and upgrade your ILD treatment
  • Examining and analyzing inflammatory ILD vs fibrotic ILD with Pfizer, Boehringer Ingelheim & The University of Michigan to identify disease signatures and key cellular players in their development and progression to help tailor your drug development approach